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Abstract
Angiogenesis, the development of new blood vessels, is essential for tumour growth; this process is stimulated by the
secretion of numerous growth factors including platelet derived growth factor (PDGF). PDGF signalling, through its receptor
platelet derived growth factor receptor (PDGFR), is involved in vessel maturation, stimulation of angiogenesis and
upregulation of other angiogenic factors, including vascular endothelial growth factor (VEGF). PDGFR is a promising target
for anti-cancer therapy because it is expressed on both tumour cells and stromal cells associated with the vasculature.
MLN0518 (tandutinib) is a potent inhibitor of type III receptor tyrosine kinases that demonstrates activity against PDGFRa/b,
FLT3 and c-KIT. In this study a multi-parametric MRI and histopathological approach was used to interrogate changes in
vascular haemodynamics, structural response and hypoxia in C6 glioma xenografts in response to treatment with MLN0518.
The doubling time of tumours in mice treated with MLN0518 was significantly longer than tumours in vehicle treated mice.
The perfused vessel area, number of alpha smooth muscle actin positive vessels and hypoxic area in MLN0518 treated
tumours were also significantly lower after 10 days treatment. These changes were not accompanied by alterations in vessel
calibre or fractional blood volume as assessed using susceptibility contrast MRI. Histological assessment of vessel size and
total perfused area did not demonstrate any change with treatment. Intrinsic susceptibility MRI did not reveal any difference
in baseline R2* or carbogen-induced change in R2*. Dynamic contrast-enhanced MRI revealed anti-vascular effects of
MLN0518 following 3 days treatment. Hypoxia confers chemo- and radio-resistance, and alongside PDGF, is implicated in
evasive resistance to agents targeted against VEGF signalling. PDGFR antagonists may improve potency and efficacy of
other therapeutics in combination. This study highlights the challenges of identifying appropriate quantitative imaging
response biomarkers in heterogeneous models, particularly considering the multifaceted roles of angiogenic growth factors.
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Introduction
Tumour growth is dependent upon angiogenesis, the de-
velopment of new blood vessels, to provide a nutritive blood
supply [1]. This process is stimulated by the secretion of numerous
growth factors by tumour cells, endothelial cells and tumour
associated macrophages [2]. Tumour vasculature is structurally
irregular, with vessels being more tortuous, fragile, dilated and
hyperpermeable in comparison to normal blood vessels [3].
Considering their critical role in tumour development and
progression, angiogenic growth factors are the target for many
novel cancer therapeutics.
The platelet derived growth factor (PDGF) family of growth
factors exert their cellular effects by binding to, and activating, the
structurally related tyrosine kinase receptors PDGFRa and
PDGFRb [4]. PDGF/PDGFR signalling is involved in vessel
maturation and the development of an ordered vascular hierarchy.
It has also been shown to stimulate angiogenesis [5] and
upregulate the expression of other angiogenic factors, such as
vascular endothelial growth factor (VEGF) [6]. Paracrine signal-
ling between PDGF-BB, expressed by vascular endothelial cells,
and PDGFRb, expressed by mural cells, plays a central role in the
recruitment of pericytes and the stabilisation of blood vessels [7,8].
PDGF/PDGFR signalling also acts on many other components of
a tumour and its microenvironment, including the autocrine and
paracrine stimulation of tumour cells resulting in enhanced cell
growth and motility [4], and the regulation of interstitial fluid
pressure (IFP) [9]. Targeting PDGF/PDGFR signalling thus
represents an attractive anti-tumour strategy.
MLN0518 (tandutinib, Millennium Pharmaceuticals Inc, Cam-
bridge, MA, USA) is a potent, ATP-competitive and reversible
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e63024
inhibitor of type III receptor tyrosine kinases that crosses the blood
brain barrier and demonstrates activity against PDGFRa/b,
FLT3 and c-KIT in the submicromolar range in vitro [10].
The identification and investigation of biomarkers of treatment
response is imperative in the development of molecularly targeted
anti-cancer drugs [11]. Magnetic resonance imaging (MRI) and
quantitative immunohistochemical techniques provide an array of
biomarkers to assess the response of tumours to such agents.
Intrinsic and extrinsic contrast agents can be deployed in MRI to
assess key hallmarks of tumour vascular pathophysiology. For
example, dynamic contrast-enhanced (DCE) MRI, which uses
a contrast agent capable of leaking out of hyperpermeable tumour
blood vessels, is now routinely requested and deployed in both
clinical and experimental pharmacological tumour investigations,
and is particularly powerful for the assessment of agents targeted to
tumour vasculature [12]. Susceptibility contrast MRI uses an
intravascular contrast agent that can inform on blood vessel
calibre and fractional tumour blood volume [13]. Intrinsic
susceptibility MRI (also referred to as blood oxygen level
dependent (BOLD) MRI) exploits the paramagnetic nature of
deoxyhaemoglobin, and following administration of a high oxygen
gas, can inform about the functional (haemodynamic) nature of
the tumour vasculature [14]. The addition of histological readouts
of perfusion, blood vessel density, vessel maturation and hypoxia
provides appropriate qualification of the imaging biomarkers
investigated.
In this study, a multi-parametric MRI and histopathological
approach was used to interrogate the vascular structural and
haemodynamic response, and the hypoxic changes in C6 glioma
xenografts in response to MLN0518.
Materials and Methods
Cell Culture
C6 rat glioma cells (European Collection of Cell Cultures,
Salisbury, UK) were maintained in Ham’s F-10 medium
supplemented with 10% (v/v) foetal bovine serum and 5 mM L-
glutamine (all Invitrogen, Life Technologies, Paisley, UK).
Ethics Statement
All procedures undertaken at the Institute of Cancer Research
were approved by the Institute of Cancer Research Ethical Review
Committee and with the authority of Personal and Project
Licences issued by the UK Home Office under the Animals
(Scientific Procedures) Act 1986, and in accordance with the
United Kingdom National Cancer Research Institute guidelines
for the welfare of animals in cancer research [15]. All experiments
performed at Millennium for this study were conducted under an
approved Millennium Institutional Animal Care and Use Com-
mittee (IACUC) protocol, and animals were housed and handled
in accordance with the Guide for the Care and Use of Laboratory
Animals. Millennium is an Association for Assessment and
Accreditation for Laboratory Care International designated in-
stitution and adheres to the highest standards of ethical treatment
in animals. Tumour propagation and MRI were performed under
general anaesthesia at both institutions and every effort was made
to minimise suffering at all times.
Tumour Propagation
C6 cells (26106) were injected subcutaneously into the flanks of
female NCr nude mice under isoflurane anaesthesia. Tumour size
was monitored using callipers and growth curves were obtained for
individual tumours using the formula for ellipsoid volume
(L6W2)/2, where L and W were the two largest dimensions of
the ellipsoid. Once tumours reached 2006100 mm3 they were
randomised to receive either 20 mg/kg MLN0518 or vehicle (5%
dextrose) subcutaneously twice daily for either three or ten days.
Magnetic Resonance Imaging
Following either three or ten days treatment with 20 mg/kg
MLN0518 or vehicle, mice underwent 1H MRI performed on
either a 7T Bruker horizontal bore microimaging system
(Ettlingen, Germany) using a 3 cm birdcage coil or a Varian
Inova 7T horizontal bore system (Palo Alto, CA, USA) using
a 63 mm quadrature coil. For susceptibility contrast and intrinsic
susceptibility MRI, anaesthesia was induced with a 10 ml/kg
intraperitoneal injection of fentanyl citrate (0.315 mg/ml) plus
fluanisone (10 mg/ml (Hypnorm; Janssen Pharmaceutical Ltd.
High Wycombe, UK)), midazolam (5 mg/ml (Hypnovel; Roche,
Burgess Hill, UK)) and sterile water (1:1:2). For dynamic contrast-
enhanced MRI, anaesthesia was induced with 3–4% isoflurane in
air (2L/min) and maintained at 1–2%. For the contrast-enhanced
protocols a lateral tail vein was cannulated with a 27G butterfly
catheter (Venisystems, Hospira, Royal Leamington Spa, UK) to
enable the remote administration of either USPIO particles
(ferumoxtran-10, SineremH; Guerbet, Villepinte, France) or Gd-
DTPA (MagnevistTM; Schering, Berlin, Germany). Core body
temperature was maintained by warm air blown through the
magnet bore.
Susceptibility Contrast and Diffusion-Weighted MRI. A
rapid acquisition with relaxation enhancement (RARE) T2-
weighted sequence (field of view= 363 cm, 1286128 matrix,
2061 mm thick contiguous axial slices, 4 averages, effective echo
time (TEeff) = 36ms, repetition time (TR) = 5000 ms) was first used
for localisation of the tumour and measurement of tumour
volume. Multi-gradient echo (MGE, TR= 300 ms, 8 echo times
(TE) ranging from TE=6.2 to 28.2 ms, flip angle = 45u, 16
averages), spin echo (SE, TR= 3000 ms, 2 echo times of 8 and
80 ms, flip angle = 90u, 2 averages) and diffusion-weighted spin
echo (DWSE, 6 b-values ranging from 6 to 504 s/mm2 in the read
direction, gradient strength = 0 to 0.1T/m, gradient dura-
tion= 5 ms, gradient spacing = 25 ms, TR= 1000 ms, TE=36 ms)
images were acquired for quantification of R2*, R2 and ADC,
respectively, from 3 contiguous 1mm thick axial slices through the
largest extent of the tumour, with a 64664 matrix over a 363 cm
field of view [16]. Following acquisition of these data, USPIO
particles were administered as a bolus (200 mmol Fe/kg i.v.) and
allowed to circulate for two minutes in order to equilibrate before
a second set of MGE and SE images were acquired. The time
taken to perform the entire MRI protocol was typically
100 minutes per mouse. This protocol was performed on tumour
bearing mice treated with vehicle (n = 6 at 3 days, n = 5 at
10 days) or MLN0518 (n = 6 at 3 and 10 days). Separate cohorts
of mice were used for the two time points to enable the provision
of pathological correlates.
Intrinsic Susceptibility MRI. A morphological RARE
sequence was used for tumour localisation, following which
MGE images (field of view= 363 cm, matrix size 1286128,
TR=200 ms, 8 echo times ranging from TE= 6.2 to 28.2 ms, flip
angle = 45u, 16 averages) were acquired for quantification of R2*
from three contiguous axial slices through the largest extent of the
tumour. Carbogen (5% CO2/95% O2) was then continuously
administered via a nose piece at 1L/min; following a transition
period of at least 10 minutes a second set of MGE images were
acquired. This protocol was performed on vehicle treated (n= 5)
and MLN0518 treated (n = 6) animals.
Dynamic Contrast-Enhanced MRI. Fast spin echo T2-
weighted coronal pilot scans were acquired to locate the tumour.
Response of C6 Xenografts to MLN0518 Treatment
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DCE MRI data were acquired from a single 2 mm thick sagittal
slice through the centre of the tumour using an inversion recovery
fast low angle shot (FLASH) imaging sequence (TE= 1.3 ms,
TR=4 ms, inversion times of 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 5
and 15 s, flip angle = 20u, 2 averages), using a 646128 matrix
(subsequently zero-filled to 1286128) over a 666 cm field of view).
Gd-DTPA (0.1mmol/kg) was manually injected i.v. over 5 sec-
onds after 10 baseline scans were acquired, and image acquisition
continued for a further 70 scans [17]. This protocol was performed
on vehicle treated (n= 8) and MLN0518 treated (n= 6) animals.
MRI Analysis
Parameter estimation was undertaken using a Bayesian maxi-
mum a posteriori algorithm, which took into account the Rician
distribution of noise in magnitude MR data in order to provide
unbiased parameter estimates [18]. ADC was determined from
DWSE MRI data. Estimates of the MRI transverse relaxation
rates R2* and R2 were determined from the susceptibility contrast
MRI data. Changes in each measured relaxation rate following
delivery of USPIO (DR2* and DR2) were also evaluated, from
which fractional blood volume (fBV, %) and vessel size index (Rv,
mm) were estimated [19,20]. Estimates of R2* and DR2* from the
intrinsic susceptibility MRI data were calculated in the same
manner, to reflect changes induced by carbogen breathing. All
data were fitted on a pixel-by-pixel basis using in-house software
(ImageView developed in IDL, ITT Visual Information Systems,
Boulder, CO, USA). The median value of each parameter in each
tumour was determined. For the DCE MRI data whole tumour
ROIs were drawn and no regional segmentation performed. The
concentration of Gd-DTPA was determined from the basal T1 and
the previously measured relaxivity at 7T of 3.2/mM/s. Parametric
IAUGC (initial area under the gadolinium concentration curve)
maps were subsequently generated for the whole image [17].
Histological Analysis
Tumour bearing mice were administered 60 mg/kg hypoxia
marker pimonidazole hydrochloride (Hypoxyprobe, Burlington,
MA, USA) in phosphate-buffered saline (PBS) i.p. After at least
45 minutes 15 mg/kg of the perfusion marker Hoechst 33342
(Sigma-Aldrich, Poole, UK) in PBS was injected intravenously
through a lateral tail vein [21]. After 1 minute tumours were
rapidly excised and cut in half; one half was snap frozen and stored
in liquid nitrogen, the other was fixed in 10% formalin in saline
(v/v) and embedded in paraffin wax.
Hoechst 33342 fluorescence signals from whole frozen tumour
sections (10 mm, two per tumour, 15 animals per treatment group)
were recorded at 365 nm using a motorised scanning stage (Prior
Scientific Instruments, Cambridge, UK) attached to a BX51
microscope (Olympus Optical, London, UK) driven by CellP (Soft
Imaging System, Mu¨nster, Germany). In addition, individual
images from localised regions of each section were acquired. From
these images the vascular morphology was visualised and the
largest vessel diameter measured using CellP [22].
The same sections were then processed for the simultaneous
detection of pimonidazole adducts and vascular endothelial
marker CD31 [21]. Sections were first incubated with 2% (w/v)
BSA/5% (v/v) goat serum in PBS for 1 hour to block any non-
specific antibody binding, and then with goat anti-mouse CD31
antibodies (MEC 13.3, BD Biosciences, Oxford, UK, 1:100)
overnight at 4uC. Sections were washed with 0.1% (v/v) Tween-20
in PBS, then incubated with Alexa 546-conjugated goat anti-rat
secondary antibodies (Invitrogen, 1:500) and Hypoxyprobe-1 plus
FITC-conjugated mouse monoclonal antibodies (Hypoxyprobe
Inc., 1:200) at 37uC for 4 hours, protected from light. Following
washing the sections were mounted in Vectashield mounting
medium (Vector Laboratories, Peterborough, UK) with a coverslip.
Regions of pimonidazole adduct formation were detected at 450–
490 nm and CD31 expression detected at 510–560 nm using the
same fluorescence microscope system and stage co-ordinates.
Composite images of whole tumour sections were recorded,
allowing the pimonidazole and CD31 images to be subsequently
overlaid on the Hoechst 33342 images. Fluorescent particles were
detected above a constant threshold and the area of the tumour
section with Hoechst 33342, pimonidazole adduct or CD31
fluorescence was determined and expressed as a percentage of the
whole tumour section. Co-localisation of Hoechst 33342 (perfused
vessels) and CD31 (total vessels) was also assessed and expressed as
a percentage total vessels perfused and a total perfused vessel area.
Alpha smooth muscle actin (a-SMA) immunohistochemistry
was performed on 5 mm formalin-fixed paraffin-embedded (FFPE)
sections (n = 12 per treatment group) using mouse monoclonal
anti-a-SMA antibodies (1A4, Sigma-Aldrich, Poole, UK, 1:500)
and EnVision Dual link HRP-labelled polymer (Dako, Ely, UK).
Composite images of whole tumour sections were acquired using
the same microscope system under light. Whole tumour images
were acquired to determine areas of a-SMA staining; positively
stained vessels were counted from 6 fields at 2006magnification
per tumour section [23].
FFPE sections were also stained with haematoxylin and eosin
(H&E) for the assessment and quantification of necrosis (n = 14 per
treatment group). Composite images of whole tumour sections
were recorded, and the degree of tumour necrosis was quantified
and expressed as a percentage of the whole tumour section area
[24].
Statistical Analysis
Results are presented as the mean 61 standard error of the
mean (s.e.m.). Significance testing used a Student’s unpaired t-test
or Mann-Whitney test with a 5% confidence level to compare
vehicle and MLN0518 treated tumours at the study endpoint.
Results
Mean growth curves for tumours grown in mice receiving
20 mg/kg MLN0518 or vehicle, expressed as a percentage of the
tumour volume immediately prior to the first dose, are shown in
Figure 1. Individual growth curves were obtained for each tumour
and the volume doubling time calculated for the duration of
treatment [21]. The mean growth rate of tumours in mice treated
with MLN0518 for ten days (mean doubling time 5.760.2 days)
was significantly slower than tumours in vehicle treated mice
(4.560.3 days, p,0.01).
At the end of the ten day treatment period tumours were
investigated by MRI. Representative parametric maps of apparent
diffusion coefficient (ADC), a measure of the magnitude of
Brownian water diffusion within tissue and an imaging biomarker
of cellularity, fractional blood volume (fBV) and vessel size index
(Rv) are shown in Figure 2. A summary of the data determined for
each quantitative MR imaging biomarker is presented in Table 1.
Susceptibility contrast and diffusion-weighted MRI demonstrated
no significant differences in the imaging biomarkers fBV, Rv and
ADC and between vehicle and MLN0518 treated tumours.
Quantification of total Hoechst 33342 uptake and vessel size
measurements taken from Hoechst 33342 stained tumour sections
also showed no significant differences in total perfusion and vessel
size, respectively, with MLN0518 treatment (Table 2).
Assessment of the co-localisation of Hoechst 33342 and CD31
(Figure 3A, Table 2) revealed that the percentage of the total
Response of C6 Xenografts to MLN0518 Treatment
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vessels perfused at the time of Hoechst 33342 injection was 17.1%
lower in MLN0518 than vehicle treated tumours (p,0.01), which
equated to a 37.5% reduction in an overall perfused vessel area in
treated versus control tumours (p,0.01). However, neither the
Hoechst 33342 perfused area nor the total CD31 positive
endothelial cell area significantly differed between vehicle and
MLN0518 treated tumours (quantification not shown). Despite
having a lower perfused vessel area, MLN0518 treated tumours
were 25.3% less hypoxic than control tumours as assessed by
pimonidazole adduct formation (p,0.05). Immunohistochemistry
demonstrated a significant reduction in alpha smooth muscle actin
positive blood vessels in MLN0518 treated tumours compared to
vehicle treated tumours (p,0.05, Table 2, Figure 3B). H&E
staining revealed no difference in necrosis between the groups
(Table 2).
In light of the MLN0518-induced alteration in perfused vessel
area, vascular maturation and hypoxia, intrinsic susceptibility
MRI was performed on a separate cohort of C6 tumour bearing
mice treated with either vehicle or 20 mg/kg MLN0518. There
was no difference in the baseline relaxation rate R2* or in the
change in R2* induced by carbogen breathing between vehicle
and MLN0518 treated tumours. Similarly, the percentage of
voxels with a negative DR2*, representing oxygenation of the
haemoglobin, was not significantly different between the treatment
groups (Table 3).
Tumour growth was also delayed by treatment with MLN0518
over three days. As was observed after ten days treatment,
MLN0518 treated tumours demonstrated a 30.8% smaller overall
perfused vessel area and were 37.0% less hypoxic than vehicle
treated tumours. Susceptibility contrast MRI did not reveal any
change in Rv, fBV or ADC at this time point (data not shown).
Dynamic contrast-enhanced MRI performed following three days
treatment with MLN0518 or vehicle revealed that the initial area
under the gadolinium concentration curve (IAUGC) was signifi-
cantly lower in tumours in MLN0518 treated mice than in control
tumours (p,0.05, Figure 4).
Discussion
PDGF/PDGFR signalling is an attractive target for anti-cancer
therapy; it has a pleiotropic role on the tumour microenvironment,
principally in vascular maturation, but it also has direct effects on
tumour cells and hypoxia [4,7,8,25]. Glioblastoma multiforme
(GBM), one of the most vascularised human tumours [26],
expresses both PDGF receptors and their ligands and demon-
strates altered PDGF pathway signalling [27]. Typically, PDGFRa
is highly expressed by tumour cells and PDGFRb is preferentially
expressed by vascular endothelial and mural cells within tumours.
However, PDGFRb has been shown to be expressed in 50% of
tumour cells in addition to 65% of peritumoural endothelial cells
in GBM [28]. Co-expression of PDGF and both receptors is an
indication that autocrine/paracrine signalling plays an important
role in glial tumour establishment and development [29,30].
Consequently, the C6 glioma xenograft model was utilised in this
study combining multi-parametric MRI and quantitative histopa-
thology to assess the response to MLN0518.
Tumour growth in mice bearing C6 xenografts was suppressed
by twice daily treatment with 20 mg/kg MLN0518. This growth
inhibition was accompanied by a significant reduction in the
number of a-SMA positive tumour blood vessels and a reduction
in the percentage of tumour vessels perfused at the time of tumour
excision, demonstrating that target inhibition had been achieved
Figure 1. C6 tumour growth is slowed by MLN0518 treatment.
The growth rate of tumours in mice treated with 20 mg/kg MLN0518
was significantly slower than tumours in vehicle treated mice over
10 days. Tumour doubling times were calculated on an individual
tumour basis (n = 15 per treatment group). Mean 61s.e.m.
doi:10.1371/journal.pone.0063024.g001
Figure 2. Diffusion-weighted and susceptibility contrast MRI of
C6 tumours treated with MLN0518. Parametric maps of apparent
diffusion coefficient (ADC, top panel), fractional blood volume (fBV,
middle panel) and vessel size index (Rv, bottom panel) from C6
xenografts in mice treated with vehicle or 20 mg/kg MLN0518 for
10 days show no clear differences between vehicle and treated
tumours. Representative maps are shown.
doi:10.1371/journal.pone.0063024.g002
Table 1. Summary of the quantitative MRI biomarkers
acquired from diffusion-weighted and susceptibility contrast
MRI of C6 xenografts in mice treated with vehicle or 20 mg/kg
MLN0518 for 10 days.
MRI Biomarker Vehicle 20mg/kg MLN0518
ADC (x1026mm2/sec) 917625 921643
Fractional blood volume (%) 3.760.5 4.560.6
Vessel size index (mm) 23.862.7 21.964.7
ADC = apparent diffusion coefficient. Mean of median parameter values from
each tumour 6 1s.e.m. (n$5 per treatment group).
doi:10.1371/journal.pone.0063024.t001
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and that inhibition of PDGFR signalling with MLN0518 has an
anti-vascular effect. However, the changes in growth rate and
vascular histological parameters following treatment with
MLN0518 were not reflected in the biomarkers afforded by
susceptibility contrast or intrinsic susceptibility MRI.
No difference in vessel calibre was observed between control
and MLN0518 treated tumours using susceptibility contrast MRI
(Rv) or by histological vessel size measurement. Considering the
role of PDGF in vascular maturation and developing a vascular
hierarchy, coupled with evidence that the number of tumour
blood vessels possessing a smooth muscle element to their wall was
lower in treated tumours than controls, an increase in vessel
calibre following MLN0518 treatment was anticipated [31].
However, it is possible that the pericytes present in these tumours
are structurally or functionally abnormal [32] and therefore any
reduction in pericyte coverage does not elicit a significant effect on
vessel calibre. Regions of high fBV detected by MRI were spatially
correlated with areas of high Hoechst 33342 uptake, typically at
the tumour rim; however neither fBV nor total Hoechst 33342
perfused area demonstrated any significant differences with
treatment. A reduction in fBV may have been anticipated when
considering the role of MLN0518 as a vascular targeting agent,
causing an overall loss of vascular integrity and anti-angiogenic
effects [5,6,33], but given the anti-maturation activity specifically
associated with PDGFR inhibition [7,8] the relative increase in
more immature vessels post-treatment could equate to increased
fBV. These opposing predicted effects of PDGFR inhibition on
tumour blood volume may explain the lack of an overall change in
fBV and Hoechst 33342 perfused area. Perfused vessel area was
lower in treated tumours, it could therefore be concluded that
there is increased vascular redundancy in MLN0518 treated
tumours. This elevation in unperfused vessels may be as a result of
vascular collapse following a loss in vascular integrity as a result of
PDGFR inhibition [33].
Quantification of ADC, a measure of the magnitude of
Brownian water diffusion within tissue and an imaging biomarker
of cellularity, demonstrated no difference between control and
MLN0518 treated tumours, indicating that cellular integrity was
maintained during the anti-tumour effect of MLN0518 [34]. This
was corroborated by quantification of necrosis from H&E stained
tissue sections, demonstrating no difference in the percentage
necrosis between the groups.
Intrinsic susceptibility MRI exploits the presence of para-
magnetic deoxyhaemoglobin in erythrocytes and can be used to
assess the change in the oxygenation of haemoglobin induced by
carbogen breathing. However, global tumour DR2* induced by
carbogen breathing and the proportion of voxels in which DR2*
was negative, indicating a replacement of paramagnetic deox-
yhaemoglobin with diamagnetic oxyhaemoglobin and therefore
indicative of perfused vasculature, did not change with MLN0518
treatment.
The presence of tumour hypoxia in solid tumours is associated
with resistance to radiation therapy and chemotherapy, the
selection of more invasive and metastatic clones, and poor patient
prognosis [35,36]. Assuming that the oxygenation of haemoglobin
is proportional to the arterial blood oxygen pressure, and therefore
in equilibrium with tissue oxygen tensions, static intrinsic
Table 2. Summary of the histological biomarkers assessed in
C6 xenografts in mice treated with vehicle or 20 mg/kg
MLN0518 for 10 days.
Histological Biomarker Vehicle 20mg/kg MLN0518
Hoechst vessel size (mm) 29.160.4 28.160.3
Perfused vessels (%) 42.562.3 31.762.0 **
Perfused vessel area (%) 1.960.2 1.260.1 **
Pimonidazole (%) 10.961.0 7.860.6 *
a-smooth muscle
actin (vessels/field)
2.860.3 2.060.3 *
Necrosis (%) 41.262.2 41.162.4
Values are mean 6 1s.e.m. Two frozen sections per tumour were assessed for
fluorescence microscopy (n = 15 per treatment group) and a single FFPE section
per tumour for a-smooth muscle actin and necrosis assessment (n$12 per
treatment group). * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0063024.t002
Figure 3. Histological assessment of tumour response to
MLN0518. A. Tumour sections stained for the perfusion marker
Hoechst 33342 (blue), endothelial marker CD31 (red) and pimonidazole
adduct formation, a marker of hypoxia (green) demonstrate that the
hypoxic area was lower in tumours treated with 20 mg/kg MLN0518 for
10 days than vehicle treated controls. The percentage of the total
vessels perfused and the overall perfused vessel area was also lower in
treated versus control tumours. Representative composite images are
shown. B. Alpha smooth muscle actin (a-SMA) immunohistochemistry
demonstrates a significant reduction in a-SMA positive blood vessels in
MLN0518 treated tumours compared to controls. Magnification6200.
doi:10.1371/journal.pone.0063024.g003
Table 3. Summary of the quantitative MRI biomarkers
acquired from intrinsic susceptibility MRI of C6 xenografts in
mice treated with vehicle or 20 mg/kg MLN0518 for 10 days.
MRI Biomarker Vehicle 20mg/kg MLN0518
Baseline R2* (s
21) 67.264.2 84.7614.5
DR2* (s
21) 3.262.8 4.762.2
DR2* ,0 (%) 36.262.8 29.963.1
DR2* .0 (%) 40.864.4 41.863.8
Mean of median R2* and DR2* values from each tumour 6 1s.e.m. (n$5 per
treatment group). The proportion of voxels in which R2* changed significantly,
either negatively (DR2* ,0) or positively (DR2* .0), with carbogen breathing
are also shown.
doi:10.1371/journal.pone.0063024.t003
Response of C6 Xenografts to MLN0518 Treatment
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susceptibility MRI measurements of R2* is a putative method with
which to assess tumour hypoxia [14]. Hypoxia assessed by
histological detection of pimonidazole adduct formation was
significantly reduced by MLN0518 treatment. However, baseline
R2* did not differ between the treatment groups, suggesting that
intrinsic susceptibility MRI was not sensitive enough to assess this
difference. The reduction in hypoxia in the treated tumours,
despite a decrease in the perfused vessel area, suggests that the
degree of hypoxia is related to the anti-tumour efficacy of
MLN0518, with the slower tumour growth rate equating to
a smaller percentage of hypoxic tumour tissue.
Unlike MLN0518 many new clinically approved targeted
receptor tyrosine kinase inhibitors, whilst improving overall
survival as monotherapies and in combination [37,38], have
been shown in preclinical models to increase the hypoxic fraction
in distant metastases [39]. PDGF/PDGFR signalling has been
shown to be involved in evasive resistance to inhibitors of VEGF
signalling, partly as a result of the increased periendothelial
support provided by pericytes, which protects the endothelial
cells from being targeted by VEGF/VEGFR inhibition [40].
This, coupled with the role of hypoxia in evasive resistance [41],
suggests that treatment with MLN0518 may provide for an
environment that supports a less resistant and malignant tumour
phenotype and improve delivery, potency and efficacy of other
therapeutics in combination or as a monotherapy.
Having established both histological and growth inhibitory
evidence of response after ten days treatment with MLN0518,
a more acute time point of three days was selected for further
investigation into the time window of any measurable MRI
biomarker response. A similar pattern of results were observed;
tumour growth inhibition, reduced perfused vascular fraction and
reduced hypoxia, but no observable change in fBV or Rv. These
results suggest that the effects of MLN0518 occur early and are
maintained over a chronic treatment time course. DCE MRI is
widely used to assess tumour vascular response to anti-vascular
agents in oncology [42], we therefore investigated DCE MRI,
using a clinically approved low molecular weight contrast agent,
for the provision of more sensitive biomarkers of response to
PDGFR inhibition in the C6 model. A significant reduction in
tumour blood vessel permeability/flow was detected following
treatment with MLN0518, illustrating that the drug has anti-
vascular effects at this time point.
Treatment with MLN0518 demonstrated significant anti-
tumour activity against C6 glioma xenografts, coupled with
significant reductions in tumour hypoxia and perfused vessel area
that, importantly, were associated with significant target in-
hibition. However, the corresponding imaging biomarkers
afforded by susceptibility contrast and intrinsic susceptibility
MRI failed to show the anticipated changes. This can be
described as a false-negative imaging biomarker response [43].
We are therefore not recommending the deployment of these
imaging techniques for the detection of response to PDGFR
inhibition in this context; however DCE MRI appears to be
more informative regarding the anti-vascular effects of PDGFR
inhibition.
A limitation of this study is the use of an ectopic glioma
xenograft model, which does not faithfully emulate the micro-
environment, tumour-host stromal interactions and host vascu-
lature factors that affect tumour growth and therapeutic re-
sponse. Further studies should be performed in orthotopic or
transgenic tumour models, in addition to subcutaneous models,
to assess the suitability of MLN0518 and other PDGF
antagonists for use in the treatment of glioma.
This study highlights the challenges of identifying quantitative
imaging response biomarkers in heterogeneous models, particu-
larly considering the multifaceted roles of angiogenic growth
factors. For the assessment of tumour response to a novel
therapeutic a rational selection of the imaging biomarker to use
can be made taking into account the putative mechanism of
action of the drug. However, experience shows that the most
appropriate biomarker that will reveal objective tumour response
cannot always be predicted. Alternative non-invasive imaging
methods that may be more informative in the assessment of
PDGFR inhibition in tumours may include measurement of
interstitial fluid pressure (IFP) and magnetic resonance elasto-
graphy (MRE).
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